Physician profile
Paul Corona
NPI 1194876219
$21,772.60
in general payments reported to CMS, 2019-2025
35 companies · $2,577 in 2025
The $2,577 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,877 · 2020: $1,112 · 2021: $1,496 · 2022: $2,378 · 2023: $6,963 · 2024: $5,369 · 2025: $2,577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,404 · Consulting Fee: $6,505 · Education: $1.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,403.95 |
| Consulting Fee | $6,505.28 |
| Education | $1.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocomposites INC | $6,505.28 | 2023-2024 | Stimulan |
| Abbvie INC. | $2,334.99 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $2,174.67 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $1,296.31 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $1,293.28 | 2024-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $959.63 | 2019-2020 | |
| Tris Pharma INC | $751.32 | 2023-2025 | Dyanavel Xr, Quillivant |
| Lundbeck LLC | $733.22 | 2021-2025 | Rexulti, Brintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $731.82 | 2021-2025 | Caplyta |
| Almatica Pharma LLC | $698.38 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Alkermes, INC. | $665.98 | 2021-2025 | Aristada, Lybalvi |
| Corium, LLC | $549.29 | 2021-2025 | Azstarys, Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $542.45 | 2019-2024 | Trintellix |
| Bausch Health US, LLC | $524.10 | 2019-2025 | Aplenzin |
| Axsome Therapeutics, INC. | $424.82 | 2022-2024 | Auvelity |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Corona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.